SCHEMBL900421

SCHEMBL900421

CCCOc1cccc(C(O)c2nc3ccccc3s2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.58
MAPK1 P28482 3/20 0.56
TSHR P16473 2/20 0.56
GAA P10253 2/20 0.56
MAPT P10636 3/20 0.47
GPBAR1 Q8TDU6 2/20 0.44
CYSLTR1 Q9Y271 2/20 0.44
ALOX5 P09917 3/20 0.43
LMNA P02545 3/20 0.42
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
NFKB1 P19838 1/20 0.42
CYP2C19 P33261 1/20 0.42
HIF1A Q16665 1/20 0.42
MEN1 O00255 1/20 0.42
GMNN O75496 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL900504 0.94 MAPK1 (0.58) HPGDMAPK1TSHRGAAGPBAR1
SCHEMBL900184 0.88 HPGD (0.58) HPGDMAPK1TSHRGAAMAPT
SCHEMBL900241 0.84 HPGD (0.53) HPGDMAPK1TSHRGAAMAPT
SCHEMBL900494 0.77 HPGD (0.70) HPGDMAPK1TSHRGAAMAPT
SCHEMBL900712 0.76 CYP2D6 (0.43) MAPK1TSHRGAAMAPTGPBAR1
SCHEMBL899810 0.75 MAPT (0.43) HPGDMAPK1TSHRGAAMAPT
SCHEMBL900511 0.75 HPGD (1.00) HPGDMAPK1TSHRGAAMAPT
SCHEMBL900480 0.75 HPGD (0.70) HPGDMAPK1TSHRGAAALOX5
SCHEMBL900715 0.74 GAA (0.73) HPGDMAPK1TSHRGAAMAPT
SCHEMBL31160 0.74 GAA (0.62) HPGDMAPK1TSHRGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2621916-B1 BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS BIOPROJET SOC CIV (FR) 2016-02-10 EP disclosed
US-9029357-B2 Benzazole derivatives as histamine H4 receptor ligands BIOPROJET (FR) 2015-05-12 US disclosed
US-20150004181-A1 Benzazole Derivatives as Histamine H4 Receptor Ligands BIOPROJET SOC CIV (FR) 2015-01-01 US disclosed
US-8802664-B2 Benzazole derivatives as histamine H4 receptor ligands BIOPROJECT (FR) 2014-08-12 US disclosed
US-20130231329-A1 Benzazole Derivatives as Histamine H4 Receptor Ligands BIOPROJET (FR) 2013-09-05 US disclosed
EP-2621916-A1 BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS BIOPROJET (FR) 2013-08-07 EP disclosed
EP-2447263-A1 Benzazole derivatives as histamine H4 receptor ligands BIOPROJET (FR) 2012-05-02 EP disclosed
WO-2012041860-A1 BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS BIOPROJET (FR) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150004181-A1 Benzazole Derivatives as Histamine H4 Receptor Ligands HRH4, HRH3, HRH2 HPGD 1014/4885MAPK1 4011/4885TSHR 386/4885
US-20130231329-A1 Benzazole Derivatives as Histamine H4 Receptor Ligands HRH4, HRH3, HRH2 HPGD 583/4885MAPK1 3365/4885TSHR 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.